Perioperative Chemotherapy for Potentially Resectable Gastric Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

749

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2018

Study Completion Date

December 31, 2018

Conditions
Gastric Cancer
Interventions
DRUG

Tegafur, Gimeracil and Oteracil Potassium Capsules;Oxaliplatin

Tegafur,Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation

DRUG

Tegafur, Gimeracil and Oteracil Potassium Capsules;Oxaliplatin

Tegafur,Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur,Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation

DRUG

Oxaliplatin; Capecitabine

Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation

Trial Locations (1)

050011

Department of General Surgery, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University

OTHER

NCT01516944 - Perioperative Chemotherapy for Potentially Resectable Gastric Cancer | Biotech Hunter | Biotech Hunter